Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori
Unknown status
Yokoyama Foundation for Clinical Pharmacology
Phase 3
2003-04-01
The eradication rate of the standard H. pylori eradication therapy (such as the triple
therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on
bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The
investigators intend to investigate whether the tailored therapy based on the two
above-mentioned factors increases the cure rate of the initial eradication therapy.
Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori
Unknown status
Hamamatsu University
Phase 3
2003-04-01
The eradication rate of the standard H. pylori eradication therapy (such as the triple
therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on
bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The
investigators intend to investigate whether the tailored therapy based on the two
above-mentioned factors increases the cure rate of the initial eradication therapy.
A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease
Completed
Takeda
Phase 1
2005-05-01
The purpose of this study is to understand how quickly lansoprazole, once daily (QD),
improves feeding in premature babies or babies less than 28 days of age.
A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin
Completed
Takeda
Phase 3
2003-07-01
The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal
complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between
lansoprazole, naproxen and celecoxib, taken once daily (QD) or twice daily (BID), in
participants with osteoarthritis taking low dose aspirin.
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
Completed
Takeda
Phase 2
2003-06-01
The purpose of this study was to compare the pharmacodynamics of intravenous (IV)
lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive
esophagitis.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
